GlycoMimetics Inc (GLYC)

NASDAQ
Currency in USD
0.257
-0.006(-3.80%)
Closed
Pre Market
0.270+0.013(+5.06%)
GLYC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Pre-Market activity
Fair Value
Day's Range
0.2570.274
52 wk Range
0.1413.500
Key Statistics
Edit
Prev. Close
0.257
Open
0.257
Day's Range
0.257-0.274
52 wk Range
0.141-3.5
Volume
188.46K
Average Volume (3m)
20.53M
1-Year Change
-92.64%
Book Value / Share
0.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLYC Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
1.000
Upside
+289.11%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

GlycoMimetics Company Profile

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Compare GLYC to Peers and Sector

Metrics to compare
GLYC
Peers
Sector
Relationship
P/E Ratio
−0.4x−1.8x−0.6x
PEG Ratio
−0.21−0.030.00
Price/Book
1.5x−0.4x2.6x
Price / LTM Sales
1,657.2x57.6x3.1x
Upside (Analyst Target)
278.8%116.2%51.5%
Fair Value Upside
Unlock20.3%7.6%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.000
(+289.11% Upside)

Earnings

Latest Release
Nov 29, 2024
EPS / Forecast
-- / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the GlycoMimetics (GLYC) Stock Price Today?

The GlycoMimetics stock price today is 0.257.

What Stock Exchange Does GlycoMimetics Trade On?

GlycoMimetics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for GlycoMimetics?

The stock symbol for GlycoMimetics is "GLYC."

What Is the GlycoMimetics Market Cap?

As of today, GlycoMimetics market cap is 16.57M.

What is GlycoMimetics Earnings Per Share?

The GlycoMimetics EPS is -0.616.

What Is the Next GlycoMimetics Earnings Date?

GlycoMimetics will release its next earnings report on 26 Feb 2025.

From a Technical Analysis Perspective, Is GLYC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.